There are three different approaches of using this axis for immunotherapy: (1) to enhance the sensitivity of the cytotoxic lymphocyte receptor NKG2D; (2) to enhance expression of NKG2D ligands on tumor cells; and (3) to eliminate the soluble NKG2D ligands from tumor environment. Here, KLRK1 is linked to neoplasm.